Skelaxin News
King Pharma Ends Suit Vs CorePharma - Forbes
2 granting CorePharma certain rights for an authorized generic version of the company's 800 mg Skelaxin product. King also said ending the lawsuit ...
S&P 500 Midday Leaders & Laggards - Houston Chronicle
The company ended its patent infringement lawsuit against CorePharma LLC over the muscle relaxant drug Skelaxin. Starbucks Corp. named chairman Howard ...
Movers Roundup: Supervalu, E-Trade - Conde Nast Portfolio
... after the company resolved one of its lingering patent disputes, ending suits against CorePharma LLC relating to King's muscle relaxant drug Skelaxin.
King Pharmaceuticals Inc. gains over 16 percent after agreement ... - TopNews
The company has terminated its patent infringement lawsuit against CorePharma over the muscle relaxant Skelaxin. The stock closed at US$12.05 with a gain of ...
Exiting My King Pharma Position with a Nice Gain - Seeking Alpha
... announced that it has agreed to end its patent infringement lawsuit against CorePharma LLC relating to its important muscle relaxant drug Skelaxin. ...
King Pharma rises on patent settlement - BusinessWeek
Core was one of several generic drug makers challenging the patent on Skelaxin. Under the agreement announced Tuesday morning, Core will be authorized to ...
King Pharma's Golden Deal - Forbes
The deal allows CorePharma certain rights for a generic version of 800 mg Skelaxin. King Pharmaceuticals gained 16.4%, or $1.70, to $12.08 in Tuesday ...
King Pharmaceutical shares up on news of patent lawsuit dismissal - CNNMoney.com
2, King will grant Core a nonexclusive license to make and sell a 400 mg metaxalone product, in what amounts to a generic form of Skelaxin. ...
King Pharma settles patent dispute, shares jump - Reuters
"While KG can breathe a small sigh of relief on its settlement agreement with CorePharma on Skelaxin, the market has overreacted to this minor stay of ...
King Pharma ends Skelaxin patent suit; CorePharma will get generic ... - Kingsport Times News
2 granting CorePharma certain rights for an authorized generic version of the company's 800 mg Skelaxin product. King also said ending the lawsuit ...
Skelaxin RSS Feed